GSK - GSK's Gepotidacin Oral Antibiotic Non-Inferior To Commonly Used Muscle-Injected Antibiotic Combo For Sexually Transmitted Infection | Benzinga
Monday, GSK plc (NYSE:GSK) released headline results from the pivotal EAGLE-1 phase 3 trial for gepotidacin, an oral antibiotic for uncomplicated urogenital gonorrhea in adolescents and adults.
The trial met its primary efficacy endpoint, with gepotidacin (oral, two doses of 3,000mg) demonstrating non-inferiority to intramuscular (IM) ceftriaxone (500mg) plus oral azithromycin (1,000mg), a leading combination treatment regimen for gonorrhea.
The result is based on a primary endpoint of microbiological response (success or failure) at the Test-of-Cure (ToC) visit 3-7 days after treatment.
Also Read: GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine.
Gonorrhea is a sexually transmitted infection caused by bacteria ...